[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 46,023
  • Shares Outstanding, K 92,046
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,384 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.19
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $0.02 on 06/01/26
  • Next Earnings Date 08/26/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.490 unch
on 07/22/26
0.600 -18.33%
on 06/25/26
-0.060 (-10.91%)
since 06/22/26
3-Month
0.490 unch
on 07/22/26
0.660 -25.76%
on 06/01/26
-0.140 (-22.22%)
since 04/20/26
52-Week
0.490 unch
on 07/22/26
1.140 -57.02%
on 09/16/25
-0.250 (-33.78%)
since 07/22/25

Most Recent Stories

More News
NurExone Announces Closing of Non-Brokered Private Placement

TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”)...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.490 (-2.00%)
NRXBF : 0.3775 (+5.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy...

See More

Key Turning Points

3rd Resistance Point 0.498
2nd Resistance Point 0.497
1st Resistance Point 0.493
Last Price 0.490
1st Support Level 0.488
2nd Support Level 0.487
3rd Support Level 0.483

See More

52-Week High 1.140
Fibonacci 61.8% 0.892
Fibonacci 50% 0.815
Fibonacci 38.2% 0.738
Last Price 0.490
52-Week Low 0.490

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.